Dilated Cardiomyopathy
Cardiovascular·MeSH: Cardiomyopathy, Dilated
Prevalence
30.0 / 100K
14 drugs in development·9 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(5)
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| ion826 | BICYCLE THERAPEUTICS PLC (BCYC) |
Preclinical(4)
Unknown(1)
| Drug | Company |
|---|---|
| laromestrocel | Longeveron Inc. (LGVN) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| lx2021 | Lexeo Therapeutics, Inc. (LXEO) |
Compare drugs
Frequently asked questions
How many drugs are in development for Dilated Cardiomyopathy?
BioSniper tracks 14 drugs in development for Dilated Cardiomyopathy across 9 companies.
How many clinical trials target Dilated Cardiomyopathy?
There are 2 clinical trials targeting Dilated Cardiomyopathy tracked by BioSniper.
What is the prevalence of Dilated Cardiomyopathy?
The estimated prevalence of Dilated Cardiomyopathy is approximately 30.0 per 100,000 population.
Deep-dive into Dilated Cardiomyopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis